Clinical Trial Update: Dose-finding Study of BI 2536 Administered in Combination With Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Cancer [Phase 1]

View source ↗

Summary

This update reports a Phase 1 dose-finding study of BI 2536 in combination with gemcitabine for locally advanced or metastatic pancreatic cancer, which has been…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• BI-2536
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pancreatic Neoplasms | Phase 1 | Status: TERMINATED